PharmaBoardroom today releases its new 51 page Slovakia Healthcare & Life Sciences Review 2016.
This report offers companies, investors, policymakers, and stakeholders crucial insight into Slovakia; a country with both political and economic stability; a Eurozone member that stands out in its region for being a member of the single currency; and, for the second half of 2016, has held the rotating presidency of the Council of the European Union. Within this stable, integrated framework, Slovakia is making a name for itself in pharmaceuticals to complement its other major industries of automotives and IT.
The report features in-depth exclusive interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on the Slovak healthcare and pharma sectors.
Featured topics include:
Ministerial Mindset: An exclusive interview with pioneering Minister of Health Tomas Drucker begins our report. He explains his plans to reform Slovakia’s healthcare system and combat the challenges of parallel trade of medicines.
Regional Strategy: Despite its comparatively small size, several MNCs are targeting Slovakia for growth due to its favourable innovation environment and ease of market access. Others are partnering with their Czech counterparts for a more regional approach.
Inward Investment: Why investment in Slovak healthcare and life sciences is a smart choice
The report features in-depth interviews with:
- Tomas Drucker, Minister of Health
- Branislav Budke, Pfizer
- Dr. Natasa Klicko, Roche
- Marianthi Psaha, Novartis
- Lucia Frzonova, Wörwag
- Roberto Simoncic, SARIO
- Dr. Leonard Sojka, Merck
- Corina Croitoru, Gedeon Richter
“Our priority in the health sector is also continuously enhancing efficiency and innovations. The basis for this priority is the transparent management of public resources.”
Tomas Drucker, Minister of Health
“As an industry, we are on our way to establishing partner relationships with the new government which actually seems to be more open to discussion than the previous one.”
Branislav Budke, Pfizer
“I am not saying that both [Slovakia and the Czech Republic] are the same, yet they are similar enough that most challenges can be solved with the same solution.”
Juan Carlos Conde, Teva
“Roche is committed to innovation – and Slovakia is the perfect country for innovation.”
Dr. Natasa Klicko, Roche
“Slovakia represents an ideal investment destination owing to our well forged reputation for political and economic stability.”
Roberto Simoncic, SARIO
“In the macroeconomic perspective, Slovakia today displays all the characteristics of a modern, successful, liberal market economy.”
Vladimir Masar, Deloitte
Click here to register and download the report.